Jonathan, Like you I have held PRLN for about a year now, and I read with interest your perspec
I welcome you and your comments to this thread.
Just out of curiosity, it what capacity did you consult for the company? As a science advisor?
I have a comment on your statement
________
...the Company must be exceedingly careful to say nothing about either AndroVir or AndroCar that would lead the FDA to claim that these are "drugs," rather than dietary supplements. Were that to happen, they could not be marketed as dietary supplements (scheduled for March-ish), and we would face years of expensive testing. This is not in our interests. This caution precludes the Comany's officially announcing virtually anything that is interesting and exciting...
__________
While what you say is true about implications for marketing as a dietary supplement, I believe it IS in our interests. In fact, I chose to invest in PRLN because I was wanted to get in before any Phase II positive results rolled in. IMO, a positive Phase II result would facilitate a collaboration and support for Phase III trials. Personally, I prefer the FDA-approval route, even though it will take several years to complete. There is plenty of opportunity for positive results to roll in and the stock to appreciate.
PRLN plans to market AndroVir and AndroCAr as dietary supplements, but they also have the possibility to co-develop them as FDA-approved products, and they definitely should do so. It sounds like their plan is to use the generated income to support further clincials. If for no other reason, it will prove to everyone that their drugs are truly effective, and the increase in income would be very substantial.
Yes, maybe it would take 3 more years or so, but if they got approval, what would PRLN be worth? And would this be a good return averaged over 3 years?
Rick |
